ストックスクリーナーアプリを入手
32.07
6.13%
-2.0227
前日終値:
$34.09
開ける：
$33.05
24時間の取引高:
206.63K
Relative Volume:
0.28
時価総額：
$2.48B
収益：
$688.00K
当期純損益:
$-170.19M
株価収益率:
-10.52
EPS:
-3.0495
ネットキャッシュフロー:
$-154.68M
1週間 パフォーマンス:
-3.73%
1か月 パフォーマンス:
-3.70%
6か月 パフォーマンス:
+79.67%
1年 パフォーマンス:
+46.72%
1日の値動き範囲:
$31.77
$34.47
1週間の範囲:
$31.62
$35.06
52週間の値動き範囲:
$10.91
$35.31
Spyre Therapeutics Inc Stock (SYRE) Company Profile
SYRE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
32.00 | 2.65B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.42 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.75 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
815.50 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.88 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.98 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | 開始されました | Mizuho | Outperform |
| 2025-12-17 | 開始されました | Citigroup | Buy |
| 2025-09-26 | 開始されました | Deutsche Bank | Buy |
| 2025-04-08 | 開始されました | Leerink Partners | Outperform |
| 2025-03-18 | 開始されました | Wolfe Research | Outperform |
| 2024-09-04 | 開始されました | Wedbush | Outperform |
| 2024-07-16 | 開始されました | Evercore ISI | Outperform |
| 2024-05-02 | 開始されました | Robert W. Baird | Outperform |
| 2024-03-01 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 開始されました | BTIG Research | Buy |
| 2023-12-11 | 開始されました | Guggenheim | Buy |
| 2023-12-11 | 開始されました | Jefferies | Buy |
| 2020-05-04 | 開始されました | Piper Sandler | Overweight |
| 2019-03-21 | 開始されました | JP Morgan | Overweight |
| 2018-09-04 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 開始されました | Evercore ISI | Outperform |
| 2018-03-14 | 繰り返されました | Needham | Buy |
すべてを表示
Spyre Therapeutics Inc (SYRE) 最新ニュース
Bull Run: Can Spyre Therapeutics Inc lead its sector in growth2025 Geopolitical Influence & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Aug Final Week: Is FORL a defensive stockChart Signals & Accurate Trade Setup Notifications - baoquankhu1.vn
Big Picture: How does Spyre Therapeutics Inc score in quality rankings2025 Price Action Summary & Verified Swing Trading Watchlists - baoquankhu1.vn
Spyre Therapeutics’ SPY002-091 Study: A Potential Game-Changer in Drug Development - MSN
Wall Street bullish on Spyre Therapeutics, Inc. (SYRE) with strong buy rating - MSN
Weekly Trades: Is FNGSs growth already priced inTrend Reversal & Growth Focused Entry Point Reports - baoquankhu1.vn
Spyre Therapeutics (SYRE) Valuation Check After Strong Recent Share Price Performance - Yahoo Finance
SYRE: BTIG Reiterates Buy Rating with $70 Price Target | SYRE St - GuruFocus
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating - Insider Monkey
Spyre Therapeutics (NASDAQ:SYRE) Trading 7.7% HigherWhat's Next? - MarketBeat
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments By Investing.com - Investing.com Nigeria
Spyre Therapeutics Advances with Phase 1 Study of SPY002-072 - MSN
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments - Investing.com
Spyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership - TipRanks
Quarterly Risk: Is Spyre Therapeutics Inc a top pick in the sectorMarket Activity Summary & High Conviction Trade Alerts - baoquankhu1.vn
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts - TradingView — Track All Markets
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 - The Manila Times
Spyre Therapeutics IncSkyline Trial In UC Completes SPY001 Enrollment Ahead Of Schedule - TradingView — Track All Markets
Six drug trials target colitis and arthritis, with first patient data in 2026 - Stock Titan
Spyre Therapeutics' CEO Sells 15,000 Shares - The Motley Fool
What technical charts say about OXYWS stockJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - moha.gov.vn
Sentiment Recap: Is Spyre Therapeutics Inc. stock cheap at current valuation2025 Pullback Review & Smart Investment Allocation Insights - Улправда
Spyre Therapeutics, Inc. (SYRE) Stock Analysis: Innovative Biotech with 86.51% Upside Potential - DirectorsTalk Interviews
Why Spyre Therapeutics Inc. stock is popular among millennials2025 Geopolitical Influence & Technical Entry and Exit Tips - Улправда
Why Spyre Therapeutics Inc. stock remains resilient2025 Market Overview & Verified Entry Point Detection - Улправда
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Is Spyre Therapeutics Inc. stock a contrarian buy2025 Pullback Review & Entry and Exit Point Strategies - Улправда
Is Spyre Therapeutics Inc. stock positioned for digital transformationPortfolio Profit Report & Capital Efficient Trading Techniques - Улправда
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Brokerages - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of “Buy” by Brokerages - Defense World
Aeglea BioTherapeutics Announces Grants of Inducement Awards - Quantisnow
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock - MarketBeat
Turtle Cameron, CEO of Spyre Therapeutics, sells $460k in shares - Investing.com Canada
Institution Moves: Is Spyre Therapeutics Inc stock a contrarian buy2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn
Spyre Therapeutics stock drops as biotech slides — what SYRE investors watch next - TechStock²
Spyre Therapeutics stock slid 6.6% into the weekend — here’s what matters before Monday’s open - TechStock²
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5% – Time to Sell? - Defense World
Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus - TechStock²
Spyre Therapeutics stock sinks 7% today: what’s pressuring SYRE and what investors watch next - ts2.tech
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5%Time to Sell? - MarketBeat
Spyre Therapeutics (SYRE) Sees Significant Decline in Stock Value - GuruFocus
Spyre Therapeutics: Validated Targets, Optimized Delivery - Seeking Alpha
CapEx per share of Spyre Therapeutics, Inc – SWB:3920 - TradingView — Track All Markets
Spyre Therapeutics Slides Despite Bullish Long-Term Hopes - TipRanks
Street Watch: Is Spyre Therapeutics Inc stock a contrarian buyQuarterly Market Summary & Daily Entry Point Trade Alerts - moha.gov.vn
Trend Recap: What makes Spyre Therapeutics Inc. stock attractive to growth fundsJuly 2025 Earnings & Detailed Earnings Play Alerts - Улправда
Why Spyre Therapeutics Inc. stock is recommended by analystsJuly 2025 Chart Watch & Safe Entry Momentum Stock Tips - Улправда
Will Spyre Therapeutics Inc. stock deliver shareholder value2025 Stock Rankings & Momentum Based Trading Ideas - Улправда
How geopolitical tensions affect Spyre Therapeutics Inc. stock2025 Biggest Moves & Technical Entry and Exit Tips - Улправда
How Spyre Therapeutics Inc. stock responds to policy changesSwing Trade & Fast Gaining Stock Strategy Reports - Улправда
Spyre Therapeutics (NASDAQ:SYRE) Upgraded at Mizuho - MarketBeat
Spyre Therapeutics Inc (SYRE) 財務データ
収益
当期純利益
現金流量
EPS
3.31%
2.06%
大文字化:
|
ボリューム (24 時間):